Discovery and Basic Research
Nan Zhao, Ph.D
Director of Non-GLP Bioanalysis
WuXi
St Paul, Minnesota
Santipharp Panmai, Ph.D.
Vice President, Head of Formulation Development
WuXi STA, a subsidiary of WuXi AppTec
San Diego, California
Description: Oligonucleotides comprise a rapidly growing class of therapeutics. However, due to their unique structure and characteristics, oligonucleotides have more technical challenges and unknown consequences for drug developers compared to more conventional drugs. In the preclinical stage, understanding absorption, distribution, metabolism, and excretion can pose unique challenges. Developing a customized approach to these DMPK studies specific to the characteristics of the oligonucleotide can provide key insights for further development in lead candidates for drug developers.